Royal Bank Of Canada Has Lowered Expectations for BeOne Medicines (NASDAQ:ONC) Stock Price

Key Points

• Royal Bank of Canada trimmed BeOne Medicines’ price target to $450 from $451 while maintaining an “outperform” rating, implying roughly 38% upside from the reported $326.58 share price.
• BeOne exceeded quarterly expectations: earnings reached $2.05 per share versus the $1.40 consensus, while revenue totaled $1.71 billion against forecasts of $1.66 billion.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and average target price of $395.85; however, insider selling—including a major CEO transaction—was reported, and the stock trades at a high P/E ratio of about 73.

BeOne Medicines (NASDAQ:ONC - Get Free Report) had its target price reduced by research analysts at Royal Bank Of Canada from $451.00 to $450.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Royal Bank Of Canada's target price indicates a potential upside of 37.79% from the company's current price.

A number of other equities analysts also recently commented on the company. Wells Fargo & Company assumed coverage on BeOne Medicines in a report on Monday, May 4th. They issued an "overweight" rating and a $400.00 price objective on the stock. JPMorgan Chase & Co. upped their price objective on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Guggenheim boosted their price target on BeOne Medicines from $420.00 to $430.00 and gave the stock a "buy" rating in a research report on Thursday. Citigroup reissued an "outperform" rating on shares of BeOne Medicines in a research note on Thursday. Finally, Nomura upgraded BeOne Medicines to a "strong-buy" rating in a report on Monday, July 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $395.85.

BeOne Medicines Stock Down 0.3%

Shares of ONC stock traded down $0.95 during trading hours on Thursday, reaching $326.58. The company had a trading volume of 149,475 shares, compared to its average volume of 279,843. BeOne Medicines has a twelve month low of $253.95 and a twelve month high of $385.22. The company has a market capitalization of $35.83 billion, a P/E ratio of 73.06 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The stock's fifty day simple moving average is $294.53 and its 200 day simple moving average is $308.67.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. As a group, sell-side analysts expect that BeOne Medicines will post 5.93 earnings per share for the current fiscal year.

Insider Activity at BeOne Medicines

In other news, CEO John Oyler sold 61,397 shares of the stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $317.67, for a total transaction of $19,503,984.99. Following the transaction, the chief executive officer owned 9,180 shares in the company, valued at approximately $2,916,210.60. This trade represents a 86.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Chan Henry Lee sold 1,044 shares of the business's stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $323.69, for a total transaction of $337,932.36. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 345,561 shares of company stock worth $105,625,947. 6.19% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds have recently added to or reduced their stakes in ONC. Mariner LLC grew its stake in shares of BeOne Medicines by 3.8% during the fourth quarter. Mariner LLC now owns 883 shares of the company's stock valued at $269,000 after buying an additional 32 shares during the last quarter. Signaturefd LLC raised its position in shares of BeOne Medicines by 10.7% in the 4th quarter. Signaturefd LLC now owns 340 shares of the company's stock worth $103,000 after purchasing an additional 33 shares during the last quarter. Farther Finance Advisors LLC grew its position in BeOne Medicines by 21.8% during the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company's stock valued at $66,000 after purchasing an additional 39 shares during the last quarter. CWM LLC increased its stake in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company's stock valued at $48,000 after purchasing an additional 39 shares in the last quarter. Finally, Steadtrust LLC raised its holdings in BeOne Medicines by 3.7% in the second quarter. Steadtrust LLC now owns 1,400 shares of the company's stock worth $399,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company's stock.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 results exceeded expectations: BeOne reported earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. Revenue reportedly surged 30% year over year, signaling strong commercial momentum. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook was raised: Management now expects fiscal-year revenue of $6.6 billion to $6.8 billion, above the $6.5 billion Wall Street forecast. The higher outlook suggests confidence in demand for BeOne’s marketed cancer treatments. BeOne raises 2026 outlook
• Positive Sentiment: Analysts raised targets: Guggenheim lifted its price target from $420 to $430 and assigned a Buy rating, while Citizens JMP raised its target from $396 to $405 and maintained a Market Outperform rating. The revisions reflect stronger earnings and growth expectations. Analyst price-target updates
• Positive Sentiment: Pipeline development advanced: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially supporting faster regulatory engagement and development of the candidate. UK Innovation Passport announcement
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at approximately $362,000 to cover tax withholding associated with vested equity awards. Because the transaction was not described as discretionary, it is a limited bearish signal. SEC insider transaction filing
• Neutral Sentiment: Valuation remains demanding: Despite improving fundamentals and a generally favorable analyst view, ONC trades at a relatively high earnings multiple, leaving the stock sensitive to any slowdown in growth or disappointing pipeline news.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source